أعرض في EDS

Tolerance of adjuvant letrozole outside of clinical trials

التفاصيل البيبلوغرافية
العنوان: Tolerance of adjuvant letrozole outside of clinical trials
المؤلفون: Jan B. Vermorken, Manon T. Huizing, Jan Lamote, D. Schallier, J. De Mey, A Meulemans, Bart Neyns, Claire Bourgain, Leonard Kaufman, Christine Collen, Robert Sacre, Christel Fontaine, G Verfaillie, J. P. De Greve
المساهمون: Medical Oncology, Laboratory of Molecular and Medical Oncology, Department of Embryology and Genetics, Radiation Therapy, Biomedical Statistics and Informatics, Medical Imaging and Physical Sciences, Pathological Anatomy, Surgery, Surgery Specializations, Internal Medicine Specializations
المصدر: Vrije Universiteit Brussel
The Breast
بيانات النشر: Elsevier BV, 2008.
سنة النشر: 2008
مصطلحات موضوعية: Oncology, medicine.medical_specialty, Nausea, medicine.medical_treatment, Antineoplastic Agents, Breast Neoplasms, law.invention, Cohort Studies, Randomized controlled trial, law, Internal medicine, Nitriles, medicine, Adjuvant therapy, Humans, Aromatase, skin and connective tissue diseases, Mastectomy, Aged, Retrospective Studies, biology, Aromatase Inhibitors, business.industry, Letrozole, General Medicine, Middle Aged, Triazoles, Arthralgia, Surgery, Postmenopause, Clinical trial, Chemotherapy, Adjuvant, biology.protein, Drug Therapy, Combination, Female, adjuvant letrozole, medicine.symptom, business, Adjuvant, Tamoxifen, medicine.drug
الوصف: Recently aromatase inhibitors have become a standard care as an adjuvant treatment for many postmenopausal patients with hormone receptor positive early breast cancer. Adjuvant letrozole was made available either immediately postoperative, after 2-3 years of tamoxifen, or as an extended treatment after 5 years of tamoxifen. Between October 2003 and October 2005, we analyzed the subjective tolerence in 185 postoperative early breast cancer patients receiving letrozole outside of a clinical trial. The most prominent toxicity was musculoskeletal pain. In addition hot flushes, increased fatigue, nausea, vomiting, anorexia, mood disturbances, vaginal dryness, hair loss and rash were also recorded. In contrast to the prospective randomized clinical trials, a high drop-out rate of 20% was documented, mainly due to aromatase inhibitor-associated arthralgia syndrome interfering significantly with the daily life of our patients. Although adjuvant aromatase inhibitors have proven to be generally superior to tamoxifen in the adjuvant setting, it is important to focus attention on the tolerance during the adjuvant therapy and to balance this against the potential benefit in individual patients. Alternative options including switching to tamoxifen remain available.
تدمد: 0960-9776
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d84ef196dd935576d98dac287ec7f99
https://doi.org/10.1016/j.breast.2008.02.006
حقوق: OPEN
رقم الأكسشن: edsair.doi.dedup.....5d84ef196dd935576d98dac287ec7f99
قاعدة البيانات: OpenAIRE
الوصف
تدمد:09609776